Portuguese 
English 
Spanish 
2 min of reading 
0 comments 
Mass Layoffs Expose Fragility of Danish Giant Amid Weight Loss Drug War
The leadership of Novo Nordisk, manufacturer of the weight loss medication Wegovy, announced on Wednesday (10) that it will lay off 9,000 people.
The layoffs are part of the company’s attempt to regain growth and defend itself against competition from the American Eli Lilly, as well as the pressure from generic drugs that are beginning to advance in the market.
According to the company, the restructuring is expected to generate savings of 8 billion Danish crowns (US$ 1.25 billion) per year, at a time when Novo Nordisk is facing a slowdown in its key obesity and diabetes medications.
-
China alone accounts for 70% of trade within the BRICS, while Brazil establishes itself as an essential supplier of food and minerals: understand how the group, which already represents nearly 40% of the world’s GDP, is changing the game.
-
Starting in May, those who do not have registered biometrics will not be able to apply for Bolsa Família, sickness benefits, or unemployment insurance: understand the new rule that changes access to benefits for millions of Brazilians.
-
A new law being voted on in Brazil proposes a minimum fare of R$ 10 per trip and R$ 2.50 per kilometer for Uber and 99 drivers, and promises to ensure they earn as well as taxi drivers did during the golden age of taxis in the country.
-
Bauer Group collapses after failed judicial recovery: 25 years, 800 vehicles, and a network of gas stations leave a debt of R$ 50 million and 100 layoffs, exposing costs, tight margins, and expensive credit in Brazil.
From Global Champion with Wegovy to Billion-Dollar Loss: How Novo Nordisk’s Rise Turned into Free Fall
The company also issued its third profit warning of the year, citing 9 billion crowns in non-recurring costs related to the restructuring.
Nova Nordisk’s meteoric rise began in mid-2021, when Wegovy was approved in the United States as the first effective drug for obesity, catapulting the company to the top of the European stock market.
However, the wave of hiring that nearly doubled its workforce in five years has become a problem. Now, the cuts represent an attempt to “return to reality.”
Analyst Simon Baker from Redburn Atlantic was straightforward: “The mass layoffs bring Novo’s employee count back to levels seen at the beginning of 2024.”
Competition from Eli Lilly, Pressure from Generics and Billion-Dollar Cuts: Challenges That Could Define Novo Nordisk’s Future
The crisis did not stop with the cuts. In July, investors withdrew US$ 70 billion from the pharmaceutical company’s market value following a new profit alert and the appointment of veteran Mike Doustdar as CEO.
Since the beginning of the year, Novo Nordisk’s shares have already fallen nearly 46%, reducing its market capitalization to around US$ 181 billion — well below the peak of US$ 650 billion recorded last year.
In practice, this means that the company has lost approximately US$ 470 billion in market value in just over a year, a drop that has called into question its global leadership position.
The case of Novo Nordisk shows how success can turn into a crisis in just a few years. A company that once led the European market now faces tough cuts and increasingly impatient investors.
And you, do you believe that Novo Nordisk still has the stamina to reinvent itself with Wegovy, or will competitor Eli Lilly completely take the lead in this billion-dollar market?
-
-
4 pessoas reagiram a isso.